PHATHOM PHARMACEUTICALS, INC. Other Noncash Income (Expense)
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Other Noncash Income (Expense) of -$2.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-06-30 was -$1.28M.
- PHATHOM PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-03-31 was -$1.60M.
- PHATHOM PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-12-31 was -$865.00K.
- PHATHOM PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-09-30 was -$1.21M.
- PHATHOM PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2025 was -$5.21M.
- PHATHOM PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2024 was -$5.10M.
- PHATHOM PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2023 was -$1.87M.
- PHATHOM PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2022 was -$1.33M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.89M 10-Q · filed 2026-07-30 | -$3.75M derived: sum of 3 quarters · filed 2026-07-30 | -$4.96M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$1.60M 10-Q · filed 2026-04-30 | -$2.47M derived: sum of 2 quarters · filed 2026-04-30 | -$3.68M derived: sum of 3 quarters · filed 2026-04-30 | -$5.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$865.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.07M derived: sum of 2 quarters · filed 2026-02-26 | -$3.40M derived: sum of 3 quarters · filed 2026-07-30 | -$5.21M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$2.53M derived: sum of 2 quarters · filed 2026-07-30 | -$4.34M 10-Q · filed 2025-10-30 | -$5.24M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$3.13M 10-Q · filed 2026-07-30 | -$4.03M derived: sum of 3 quarters · filed 2026-07-30 | -$5.26M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$1.81M 10-Q · filed 2026-04-30 | -$2.71M derived: sum of 2 quarters · filed 2026-04-30 | -$3.94M derived: sum of 3 quarters · filed 2026-04-30 | -$5.25M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$896.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.13M derived: sum of 2 quarters · filed 2026-02-26 | -$3.44M derived: sum of 3 quarters · filed 2026-02-26 | -$5.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$2.55M derived: sum of 2 quarters · filed 2025-10-30 | -$4.20M 10-Q · filed 2025-10-30 | -$4.60M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | -$1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.97M 10-Q · filed 2025-08-07 | -$3.37M derived: sum of 3 quarters · filed 2025-08-07 | -$3.68M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.65M 10-Q · filed 2025-05-01 | -$2.06M derived: sum of 2 quarters · filed 2025-05-01 | -$2.37M derived: sum of 3 quarters · filed 2025-05-01 | -$2.76M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | -$401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$712.00K derived: sum of 2 quarters · filed 2025-03-06 | -$1.11M derived: sum of 3 quarters · filed 2025-03-06 | -$1.87M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$311.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$705.00K derived: sum of 2 quarters · filed 2024-11-07 | -$1.47M 10-Q · filed 2024-11-07 | -$1.67M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$394.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | -$1.16M 10-Q · filed 2024-08-08 | -$1.36M derived: sum of 3 quarters · filed 2024-08-08 | -$1.61M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$763.00K 10-Q/A · filed 2024-06-14 | -$964.00K derived: sum of 2 quarters · filed 2024-06-14 | -$1.22M derived: sum of 3 quarters · filed 2024-06-14 | -$1.50M derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | -$201.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | -$455.00K derived: sum of 2 quarters · filed 2024-06-14 | -$738.00K derived: sum of 3 quarters · filed 2024-06-14 | -$1.33M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | -$254.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$537.00K derived: sum of 2 quarters · filed 2023-11-09 | -$1.13M 10-Q · filed 2023-11-09 | -$1.23M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$283.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$874.00K 10-Q · filed 2023-08-10 | -$975.00K derived: sum of 3 quarters · filed 2023-08-10 | -$1.16M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$591.00K 10-Q · filed 2023-05-10 | -$692.00K derived: sum of 2 quarters · filed 2023-05-10 | -$874.00K derived: sum of 3 quarters · filed 2023-05-10 | -$1.06M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$101.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | -$283.00K derived: sum of 2 quarters · filed 2023-02-28 | -$466.00K derived: sum of 3 quarters · filed 2023-02-28 | -$823.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | -$182.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | -$365.00K derived: sum of 2 quarters · filed 2022-11-09 | -$722.00K 10-Q/A · filed 2022-11-09 | -$886.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$183.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$540.00K 10-Q · filed 2022-08-02 | -$704.00K derived: sum of 3 quarters · filed 2022-08-02 | -$862.00K derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | -$357.00K 10-Q · filed 2022-05-10 | -$521.00K derived: sum of 2 quarters · filed 2022-05-10 | -$679.00K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$164.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$322.00K derived: sum of 2 quarters · filed 2022-03-01 | -$322.00K 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$158.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$158.00K 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |